TrialPath
Parkinson's disease · Washington

Parkinson's disease clinical trials in Washington

8 recruiting parkinson disease studies within range of Washington. Click any trial for full eligibility criteria and contact info.

Social & QoL Behaviors in Parkinson's Disease

NCT06385184 · Parkinson Disease
Recruiting

Adults with Parkinson's Disease experience an array of challenges and changes in daily living, behaviors, and functioning throughout the progression of their condition. The investigators want to learn more about the effects of Parkinson's Disease on individuals' social behavior and quality of life (QoL) compared to people of the same age without Parkinson's Disease.

Phase—
TypeObservational
Age40 Years
WhereWashington D.C., District of Columbia, United States
SponsorGregory Wallace
▾Tap for details
Apply

RESvEraTrol in Parkinson's Disease (RESET)

NCT07592767 · Parkinson's Disease
Recruiting

This is an exploratory phase 2a study to investigate two doses of resveratrol (JotrolTM) vs placebo in individuals diagnosed with Parkinson's Disease (PD). Participants (n=30) will be randomized 1:1:1 into 3 groups and will receive oral JotrolTM vs placebo. Study drug will be titrated to reach a final maximal dose per group and will be administered orally once daily (QD) for 3 months. The study will primarily evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics (PK/PD) of JotrolTM.

PhasePhase 2
TypeInterventional
Age55 Years – 85 Years
WhereWashington D.C., District of Columbia, United States
SponsorGeorgetown University
▾Tap for details
Apply

A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

Recruiting

Study BRT-DA01-301 is a Phase 3 multicenter, randomized, sham surgery-controlled, double-blind study to assess efficacy and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).

PhasePhase 3
TypeInterventional
Age45 Years – 75 Years
WhereScottsdale, Arizona, United States + 42 more
SponsorBlueRock Therapeutics
▾Tap for details
Apply

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

NCT06952504 · Endometrial Cancer
Recruiting

Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent. * EC is a type of cancer that starts in the tissues inside the uterus (womb) * pMMR indicates that certain normal proteins are present in the cancer cells * Advanced means the cancer has spread locally or to other parts of the body (metastatic) and cannot be removed with surgery * Recurrent means the cancer came back after surgery Sacituzumab tirumotecan (also known as sac-TMT) and pembrolizumab are the study medicines. Sac-TMT is an antibody drug conjugate (ADC). An ADC attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goal of this study is to learn if people who receive sac-TMT with pembrolizumab live longer and without the cancer getting worse compared to people who receive pembrolizumab alone.

PhasePhase 3
TypeInterventional
Age18 Years
WhereMobile, Alabama, United States + 271 more
SponsorMerck Sharp & Dohme LLC
▾Tap for details
Apply

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

NCT07174310 · Parkinson's Disease
Recruiting

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.

PhasePhase 3
TypeInterventional
Age50 Years – 85 Years
WhereBirmingham, Alabama, United States + 191 more
SponsorHoffmann-La Roche
▾Tap for details
Apply

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

NCT04165070 · Carcinoma, Non-Small-Cell Lung
Recruiting

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-0482, I-DXd, or HER3-DXd in treatment-naïve participants with advanced squamous or non-squamous NSCLC. This study is one of the pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).

PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years
WhereGilbert, Arizona, United States + 46 more
SponsorMerck Sharp & Dohme LLC
▾Tap for details
Apply

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

NCT04165798 · Carcinoma, Non-Small-Cell Lung
Recruiting

This study is referred to as the "umbrella master protocol" for pembrolizumab (MK-3475) in the treatment of non-small cell lung cancer (NSCLC). This pembrolizumab NSCLC umbrella master protocol uses a platform design and consists of this master screening study and additional substudies. Each substudy will enroll a different population of NSCLC participants.

Phase—
TypeObservational
Age18 Years
WhereGilbert, Arizona, United States + 47 more
SponsorMerck Sharp & Dohme LLC
▾Tap for details
Apply

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

NCT06841354 · Triple Negative Breast Neoplasms
Recruiting

Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.

PhasePhase 3
TypeInterventional
Age18 Years
WhereMobile, Alabama, United States + 284 more
SponsorMerck Sharp & Dohme LLC
▾Tap for details
Apply